NasdaqGS - Delayed Quote USD

QuidelOrtho Corporation (QDEL)

Compare
45.55 +1.37 (+3.10%)
At close: September 27 at 4:00 PM EDT
44.92 -0.63 (-1.38%)
After hours: September 27 at 5:34 PM EDT
Loading Chart for QDEL
DELL
  • Previous Close 44.18
  • Open 44.87
  • Bid 45.50 x 300
  • Ask 45.58 x 200
  • Day's Range 44.76 - 45.98
  • 52 Week Range 29.74 - 75.86
  • Volume 441,792
  • Avg. Volume 1,148,279
  • Market Cap (intraday) 3.063B
  • Beta (5Y Monthly) 0.08
  • PE Ratio (TTM) --
  • EPS (TTM) -27.75
  • Earnings Date Jul 31, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 56.17

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

www.quidelortho.com

7,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: QDEL

View More

Performance Overview: QDEL

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

QDEL
38.20%
S&P 500
20.30%

1-Year Return

QDEL
35.75%
S&P 500
34.27%

3-Year Return

QDEL
69.00%
S&P 500
28.79%

5-Year Return

QDEL
25.36%
S&P 500
92.71%

Compare To: QDEL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: QDEL

View More

Valuation Measures

Annual
As of 9/26/2024
  • Market Cap

    2.97B

  • Enterprise Value

    5.64B

  • Trailing P/E

    --

  • Forward P/E

    13.95

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.04

  • Price/Book (mrq)

    0.94

  • Enterprise Value/Revenue

    1.99

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -65.60%

  • Return on Assets (ttm)

    1.07%

  • Return on Equity (ttm)

    -45.48%

  • Revenue (ttm)

    2.83B

  • Net Income Avi to Common (ttm)

    -1.86B

  • Diluted EPS (ttm)

    -27.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    107.2M

  • Total Debt/Equity (mrq)

    87.31%

  • Levered Free Cash Flow (ttm)

    122.58M

Research Analysis: QDEL

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

44.00
56.17 Average
45.55 Current
64.00 High
 

Company Insights: QDEL

Research Reports: QDEL

View More
  • Raising target price to $37.00

    QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $37.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
     
  • Raising target price to $35.00

    QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $35.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
     
  • What does Argus have to say about QDEL?

    QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $35.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
     
  • What does Argus have to say about QDEL?

    QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $35.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
     

People Also Watch